Macular oedema (diabetic) - aflibercept: committee papers
01. NICE's response to comments on the Appraisal Consultation Document (ACD)
02. Consultee comments on the ACD - Bayer
03. commentator comments on the ACD - Alimera Sciences
04. Commentator comments on the ACD - Novartis
05. New evidence submitted at ACD consultation by Bayer
06. ERG critique of Bayer new evidence
|
Macular oedema (diabetic) - aflibercept: committee papers
02 June 2015 (2.37 Mb 47 sec) |
This page was last updated: 28 May 2015